










































Statin therapy inhibits remyelination in the central nervous
system
Citation for published version:
Miron, VE, Zehntner, SP, Kuhlmann, T, Ludwin, SK, Owens, T, Kennedy, TE, Bedell, BJ & Antel, JP 2009,
'Statin therapy inhibits remyelination in the central nervous system' American Journal Of Pathology, vol 174,
no. 5, pp. 1880-90. DOI: 10.2353/ajpath.2009.080947
Digital Object Identifier (DOI):
10.2353/ajpath.2009.080947
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
American Journal Of Pathology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Neurobiology
Statin Therapy Inhibits Remyelination in the Central
Nervous System
Veronique E. Miron,*† Simone P. Zehntner,‡
Tanja Kuhlmann,§ Samuel K. Ludwin,¶
Trevor Owens, Timothy E. Kennedy,†
Barry J. Bedell,‡ and Jack P. Antel*
From the Neuroimmunology Unit,* the Centre for Neuronal
Survival,† and the Brain Imaging Center,‡ Montreal Neurological
Institute, McGill University, Montreal, Quebec, Canada; the
Institute of Neuropathology,§ University Hospital, Munster,
Germany; the Department of Neuropathology,¶ Queen’s
University, Kingston, Ontario, Canada; and the Centre for
Medical Biotechnology, Institute of Medical Biology, University of
Southern Denmark, Denmark
Remyelination of lesions in the central nervous sys-
tem contributes to neural repair following clinical
relapses in multiple sclerosis. Remyelination is initi-
ated by recruitment and differentiation of oligoden-
drocyte progenitor cells (OPCs) into myelinating
oligodendrocytes. Simvastatin, a blood-brain barrier-
permeable statin in multiple sclerosis clinical trials,
has been shown to impact the in vitro processes that
have been implicated in remyelination. Animals were
fed a cuprizone-supplemented diet for 6 weeks to
induce localized demyelination in the corpus callo-
sum; subsequent return to normal diet for 3 weeks
stimulated remyelination. Simvastatin was injected
intraperitoneally during the period of coincident de-
myelination and OPC maturation (weeks 4 to 6),
throughout the entire period of OPC responses
(weeks 4 to 9), or during the remyelination-only
phase (weeks 7 to 9). Simvastatin treatment (weeks 4
to 6) caused a decrease in myelin load and both
Olig2strong and Nkx2.2strong OPC numbers. Simvasta-
tin treatment (weeks 4 to 9 and 7 to 9) caused a
decrease in myelin load, which was correlated with a
reduction in Nkx2.2strong OPCs and an increase in
Olig2strong cells, suggesting that OPCs were main-
tained in an immature state (Olig2strong/Nkx2.2weak).
NogoA oligodendrocyte numbers were decreased
during all simvastatin treatment regimens. Our
findings suggest that simvastatin inhibits central
nervous system remyelination by blocking progen-
itor differentiation, indicating the need to monitor
effects of systemic immunotherapies that can ac-
cess the central nervous system on brain tissue-
repair processes. (Am J Pathol 2009, 174:1880–1890; DOI:
10.2353/ajpath.2009.080947)
Multiple sclerosis (MS) is characterized by inflammatory
demyelinating lesions in the central nervous system
(CNS). Remyelination of such lesions, recognized by his-
topathological and in vivo imaging techniques, is consid-
ered to contribute to neural repair following clinical re-
lapses.1,2 Experimental models of CNS demyelination
indicate that remyelination is mediated by oligodendro-
cyte progenitor cells (OPCs), and requires their migration
into the lesion and differentiation into mature myelinating
phenotypes.3 OPCs have been identified in the human
adult brain and surrounding demyelinated MS lesions.4
The impact of any therapeutic agent on OPCs and remy-
elination may be a significant determinant of long-term
neurological function.
Simvastatin, a blood-brain barrier-permeable statin,5
inhibits 3-hydroxy-3-methylglutaryl co-enzyme A reduc-
tase, restricting synthesis of cholesterol and the post-
translational lipid attachments, isoprenoids. The benefi-
cial action of simvastatin in reducing initial disease
severity in an animal model of MS, experimental autoim-
mune encephalomyelitis,6 has propelled this agent into
MS clinical trials.7 The reported increase in myelin repair
in experimental autoimmune encephalomyelitis following
short-term statin therapy8 could reflect an indirect con-
sequence of immunomodulatory effects or a direct im-
pact on oligodendroglia. We have previously reported
that short-term statin treatment of human and rodent
OPCs and mature oligodendrocytes (OLGs) in vitro in-
duces process outgrowth and differentiation via isopre-
noid depletion.9 Other studies have demonstrated that
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statin treatment of adult human brain–derived OPCs also
enhances their differentiation while inhibiting prolifera-
tion.10 Prolonged exposure to statins, however, can
cause oligodendroglial process retraction through cho-
lesterol depletion, and cell death by blocking synthesis of
isoprenoids and cholesterol.9
Given the multiple in vitro effects of statins on progen-
itor cell responses that are presumed to be implicated in
remyelination, the objective of this study was to assess
whether these observations translated into effects on re-
myelination in vivo. In our current study we used oral
cuprizone administration as an in vivo model of non-im-
mune system-initiated, brain-localized demyelination and
remyelination.11,12 This model allowed us to determine
the direct effect of long-term statin therapy on remyelina-
tion, independent of its indirect effects mediated via sys-
temic immune modulation. The massive demyelination in
specific white matter tracts that ensues from oral cupri-
zone administration is reproducible and localized, facili-
tating assessment of effects of pharmacological treat-
ments on acceleration or inhibition of remyelination.13
The concomitant demyelination and OPC responses/re-
myelination observed with cuprizone administration rep-
licates what has been observed in demyelinating MS
lesions.14 This model also provides the opportunity to
study remyelination alone once the cuprizone toxin is
removed from the diet.13 Given the role of OPCs in the
remyelination process, we evaluated effects of simvasta-
tin on progenitors using the transcription factors Olig2
and Nkx2.2 as markers, and identified mature OLGs by
NogoA expression. These same markers have been used
to identify OPCs and OLGs in both MS lesions and normal
adult brain.15 The cuprizone model avoids confounding
issues such as axonal damage, blood-brain barrier
breakdown, and moderate traumatic injury with conse-
quent immune cell infiltration at the injection site.16–18
We elected to use simvastatin due to its use in MS
clinical trials,7 its ability to cross the blood-brain barrier,5
and the finding that chronic oral administration of simva-
statin in mice results in significant concentrations of statin
in the brain with resultant changes in gene expression.19
We report that simvastatin significantly inhibits the robust
remyelination that normally occurs subsequent to CNS




Animal handling and experiments were conducted ac-
cording to the Canadian Council on Animal Care guide-
lines and were approved internally by the McGill Univer-
sity Animal Care Committee. Fourteen-week-old adult
male C57BL/6J mice (Jackson Laboratories; Bar Harbor,
ME) were fed 0.2% cuprizone-supplemented chow ad
libitum (bis-cyclohexane oxaldihydrazone; Sigma, Oakville,
CA; Harlan Teklad, Madison, WI) for weeks 1 to 6, to
induce a reproducible and localized OLG cell death and
demyelination in the corpus callosum. Remyelination in
cuprizone-treated mice was achieved by returning the
mice to a normal diet for three subsequent weeks (weeks
7 to 9). OPC proliferation, recruitment, and differentiation
are observed before return to normal diet (week 4 of
treatment).13 A subset of mice received daily i.p. injec-
tions of 2 mg of simvastatin/kg of body weight (Calbio-
chem, San Diego, CA) or vehicle (dimethyl sulfoxide)
dissolved in sterile 0.9% sodium chloride solution. We
administered the active metabolite of the drug thereby
bypassing the need for oral ingestion/metabolism; both
orally administered simvastatin that has been metabo-
lized, and the injected active metabolite, have the poten-
tial to be partially reverted back to the parent drug in
tissue to the same extent.20 Simvastatin was adminis-
tered for weeks 4 to 6 during the period of concomitant
demyelination and remyelination, from weeks 4 to 9 dur-
ing the entire period of OPC responses, or during the
remyelination-only period (weeks 7 to 9) (Figure 1). Of
cuprizone-treated animals, nine were treated with simva-
statin and nine with vehicle. Of the animals on normal
diet, six were treated with simvastatin and six with vehi-
cle. When assessing myelin levels in the corpus callo-
sum, there was no significant difference between animals
treated with cuprizone alone and those treated with cu-
prizone and the vehicle used to reconstitute the simva-
statin (data not shown), demonstrating that the vehicle
did not have any impact on myelin processes in cupri-
zone-fed animals. No adverse side effects or gross be-
havioral abnormalities were observed in any treatment
group throughout the experiments.
Immunohistochemistry
Animals were anesthetized with ketamine (125 mg/kg)-
xylazine (25 mg/kg) and exsanguinated by intracardial
perfusion with PBS. Brains were extracted and fixed in
10% neutral-buffered formalin, dehydrated through graded
alcohols and xylene, and subsequently embedded in
Figure 1. Treatment protocol. Cuprizone was administered for weeks 1 to 6
to induce demyelination in the corpus callosum (CC). A: OPC proliferation/
maturation in the CC begins at week 4 of cuprizone treatment, during
concomitant demyelination. Once animals are returned to normal diet (week
7), robust remyelination occurs (weeks 7 to 9, B). Simvastatin (2 mg/kg/day)
was injected daily during the period of concomitant demyelination and OPC
maturation (weeks 4 to 6, C), during the entire remyelination period (weeks
4 to 9, D) or during the remyelination only phase (weeks 7 to 9, E). As
controls, animals on normal diet received simvastatin therapy from weeks 4
to 6 or 4 to 9.
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paraffin wax. Coronal brain sections of 5 m were de-
waxed and rehydrated. Four sections from each animal
were stained with luxol fast blue (LFB) overnight in a
warm humid incubator, rinsed with 95% ethanol, lithium
carbonate, 70% ethanol, and water. Sections were coun-
terstained with H&E and subsequently dehydrated. Im-
munohistochemistry staining was performed using a Lab
Vision Autostainer 360 (LabVision, Fremont, CA) after
rehydration and heat-induced antigen retrieval in boiling
10 mmol/L citrate buffer pH 6.1 (LabVision) or EnVision
retrieval buffer pH 6 (Dako, Mississauga, Ontario, Can-
ada) at elevated pressure. All samples were treated for
endogenous peroxidase activity with 0.3% H2O2 followed
by blocking with LVBlock (LabVision). Sections were in-
cubated with the appropriate antibodies: mouse anti-
myelin basic protein (MBP; Sternberger monoclonals,
Lutherville, MD), rabbit anti-glial fibrillary acidic protein
(GFAP; Medicorp, Montreal, Quebec, Canada), rabbit
anti-ionized calcium-binding adaptor molecule-1 (IBA-1;
WAKO Chemicals USA, Richmond, VA), rabbit anti-Olig2
(IBL, Gunma, Japan), mouse anti-Nkx2.2 (clone 74.5A5;
Developmental Studies Hybridoma Bank, University of
Iowa, IA), and rabbit anti-neurite outgrowth inhibitor pro-
tein A (NogoA; Chemicon, Temecula, CA). Primary anti-
bodies were detected using avidin-biotin (LabVision), LV
polymer (LabVision), or EnVision (Dako) amplification,
followed by visualization with horseradish peroxidase-
catalyzed 3-amino-9-ethylcarbazole (LabVision) chromo-
gen deposition. Control sections showed low non-spe-
cific staining. All sections were blindly digitized using a
Nikon Eclipse 55i microscope (Nikon Canada, Missis-
sauga, ON, Canada) equipped with a QICAM 12-bit Fasr
1394 digital camera (QImaging, Surrey, BC, Canada).
Automated high-resolution whole-section imaging was
performed using Mirax Scan (Carl Zeiss Microimaging,
Inc., Gottingen, Germany).
Controls for Simvastatin Biological Activity
We verified the ability of simvastatin to decrease choles-
terol levels in vivo by measuring serum cholesterol levels.
Blood was collected from the mice before perfusion and
allowed to coagulate on ice for a few hours. Serum was
collected and homogenized with chloroform-methanol
(2:1), solutions were centrifuged for 10 minutes at 10,000
rpm, and the organic phase was isolated and centri-
fuged. Solvent was evaporated overnight, and pellets of
concentrated cholesterol were re-dissolved in reaction
buffer. Cholesterol levels were assessed using the Am-
plex Cholesterol Assay (Molecular Probes, Eugene, OR)
according to the manufacturer’s instructions.
Analysis
LFB staining of the medial corpus callosum was blindly
assessed for demyelination through the microscope.
Scores were assigned as follows: 0 to fully myelinated
sections, 1 to sections with mild demyelination, 2 to sec-
tions with scarce myelin, 3 for completely demyelinated
medial corpus callosum, and 4 for demyelination of me-
dial and more lateral corpus callosum. A similar scoring
system has been previously used to assess LFB histo-
chemical stains.12 The area of MBP immunohistochemi-
cal staining was assessed objectively using an optical
density image (Scion Image software) calibrated to 20
objective image. OPCs (Olig2strong, Nkx2.2strong), OLGs
(NogoA), astrocytes (GFAP), and microglia (IBA-1)
were blindly counted in the medial corpus callosum in
10 to20 objective images using a calibrated grid with
Adobe Photoshop software (San Jose, CA). Data are
represented as average score/number of immunopositive
cells per mm2/area of MBP staining (m2)  SEM. All
comparisons between conditions were performed using
one-way analysis of variance followed by Newman-Keuls
multiple comparison posthoc test. Normality was as-
sessed using Bartlett’s test for equal variances. Probabil-
ity values 0.05 were considered statistically significant.
Results
Simvastatin Is Functionally Active
The dose of statin used in our study was in the same
range as used in previous experimental immunomodula-
tory directed studies.6,8 Statin was confirmed to be func-
tionally active in vivo by the measure of serum cholesterol
levels. We observed a significant decrease following
long-term simvastatin treatment of animals on normal diet
(weeks 4 to 9, 7.9 g/ml) relative to vehicle-treated con-
trol (139.8 g/ml). This was also noted when simvastatin
was administered to cuprizone-fed animals (weeks 4 to 9,
17.8 g/ml; weeks 7 to 9, 34.1 g/ml) as compared with
cuprizone alone (87.6 g/ml).
Effect of Simvastatin Treatment on Myelin Load
To assess the effect of simvastatin on remyelination and
myelin maintenance in the cuprizone model (Figure 1),
demyelination in the medial corpus callosum (CC) was
scored following LFB histochemistry, and myelin load in
the medial CC was quantitatively assessed by determin-
ing the area of staining of MBP in digitized immunohisto-
chemical sections.
Long-Term Simvastatin Treatment Hampers Myelin
Maintenance under Non-Demyelinating Conditions
We first determined whether simvastatin could impact
ongoing myelin maintenance processes under non-de-
myelinating conditions. Short-term simvastatin therapy
alone (weeks 4 to 6) did not induce any notable effects on
demyelination/myelin load in animals on normal diet (Fig-
ure 2B). However, long-term simvastatin therapy alone
given to animals on normal diet (weeks 4 to 9) did signif-
icantly decrease LFB staining (Figure 2A), increase de-
myelination score (Figure 2C), and reduce MBP levels
(Figure 2, A and D) relative to vehicle-treated control,
indicative of diminished myelin content.
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Simvastatin Treatment Decreases Myelin Load during
Concomitant Demyelination and Initial OPC
Proliferation/Maturation
As expected, 6 weeks of oral cuprizone treatment (Fig-
ure 1A) decreased LFB staining and increased the de-
myelination score in the medial CC in comparison with
animals on normal diet (Figure 2B). Simvastatin treatment
during weeks 4 to 6, ie, the period of concomitant demy-
elination and OPC proliferation/maturation13 (Figure 1, B
and C), induced an additional decrease in LFB staining
and increase in demyelination score, relative to cupri-
zone-treated animals that were administered only the
vehicle used to dilute simvastatin (Figure 2B), suggesting
either enhanced demyelination or inhibition of initial OPC
responses by simvastatin. This was addressed by deter-
mining the impact of simvastatin on the post-cuprizone
remyelination phase, discussed below.
Simvastatin Treatment Impedes Post-Cuprizone
Remyelination
On return to normal diet for 3 weeks subsequent to
cuprizone administration (Figure 1B, week 9), there was
an increase in LFB staining (Figure 2A), a significant
decrease in demyelination score (P  0.05, Figure 2B),
and an increase in area of MBP staining in the medial CC
(Figure 2, A and D) when compared with immediately
post-cuprizone administration (week 6), indicative of re-
myelination.13 Treatment with simvastatin either during
the entire period of OPC responses (weeks 4 to 9, Figure
Figure 2. Simvastatin inhibits remyelination in cuprizone-demyelinated corpus callosum. A: Luxol fast blue (LFB) histochemistry (left panels) and myelin basic
protein (MBP) immunohistochemistry (right panels) were used to evaluate myelin content in the corpus callosum (CC). Representative images of sections of
animals treated with vehicle (Veh) or simvastatin (Simva) for weeks 4 to 9 or weeks 7 to 9. Scale bar  200 m. B: Average LFB demyelination scores ( SEM)
for animals treated with vehicle or simvastatin during weeks 4 to 6. By week 6, simvastatin treatment of animals on normal diet (black bars) had no effect on myelin
load relative to vehicle control. Cuprizone administration (gray bars) significantly increased demyelination score relative to vehicle-treated animals on normal diet
(black bars). Simvastatin treatment of cuprizone-fed animals further increased demyelination scores. C: Average LFB demyelination scores ( SEM) for animals
treated with vehicle or simvastatin for weeks 4 to 9 or 7 to 9. Long-term simvastatin treatment of animals on normal diet (black bars) significantly increased
demyelination score. Cuprizone treated animals (gray bars) injected with vehicle still demonstrated an overall increase in demyelination at week 9 relative to
control, yet some recovery was observed as compared with week 6 (B). Simvastatin treatment (weeks 4 to 9, 7 to 9) produced persistent increases in demyelination
scores relative to cuprizone alone. D: Average area of MBP staining in the CC (m2  SEM) for animals treated with vehicle or simvastatin during weeks 4 to 9
or 7 to 9. Simvastatin treatment of animals on normal diet (black bar) caused a significant reduction in area of MBP staining relative to vehicle control. By week
9, MBP levels in the CC of animals treated with cuprizone (gray bar) and vehicle had recovered to those observed in animals on normal diet. Simvastatin treatment
(weeks 4 to 9, 7 to 9) of cuprizone-fed animals resulted in a reduced area of MBP staining relative to cuprizone alone. Analysis of variance P values 0.001 for
LFB scores and 0.0019 for MBP quantification. ns P  0.05, *P  0.05, **P  0.01, ***P  0.001.
Myelin Responses to Long-term Statin Therapy 1883
AJP May 2009, Vol. 174, No. 5
1D) or during the remyelination-only phase (weeks 7 to 9,
Figure 1E) was associated with a decrease in LFB stain-
ing (Figure 2A), significant increase in demyelination
score (Figure 2C), and decrease in area of MBP staining
(Figure 2, A and D) relative to vehicle-treated animals,
thereby indicating reduced myelin content and inhibition
of remyelination by simvastatin.
Effects of Simvastatin Treatment on
Oligodendrocyte Progenitor Cells
Given the role of OPCs in the remyelination process, we
evaluated the effects of simvastatin on oligodendroglial
cells, by identifying OPCs by high expression levels
(‘strong’) of the oligodendrocyte specification transcrip-
tion factors Olig2 and Nkx2.2,15,21,22 and determined the
average number of strongly positive cells in the medial
CC. In the normal CC, both Olig2strong and Nkx2.2strong
OPCs followed a random distribution pattern (Figure 3,
A and B).
Simvastatin Treatment Influences Progenitor
Numbers and Differentiation State under
Non-Demyelinating Conditions
Animals on a normal diet demonstrated a significant
increase in Olig2strong cells (P  0.01, Figure 3C, Figure
4, A and B) and a significant decrease in Nkx2.2strong
cells (P  0.001, Figure 3D, Figure 4, A and B) at week 9
as compared with week 6. Since Olig2strong/Nkx2.2weak
cells are regarded as immature OPCs22; these findings
may reflect continuous infiltration of immature OPCs into
the normal adult white matter. These cells may eventually
contribute to the mature OLG pool over time, as contin-
uous replacement of OLGs has been observed in normal
adult CNS.23,24 Both short-term and long-term simvasta-
tin treatment of animals on normal diet (weeks 4 to 6, 4 to
9) caused an increase in the numbers of Olig2strong (Fig-
ure 3C, Figure 4, A and B) and Nkx2.2strong cells (Figure
3D, Figure 4, A and B) relative to vehicle-treated controls.
This may suggest that simvastatin treatment caused
OPCs to be maintained in a pre-OLG state (Olig2strong
and Nkx2.2strong).22 These cells did not contribute to
the OLG pool or myelin maintenance as a decrease in
myelin content was observed with long-term simvasta-
tin treatment.
Simvastatin Treatment Reduces Progenitor Numbers
during Concomitant Demyelination and Progenitor
Infiltration
Cuprizone administration for 6 weeks caused an in-
crease in Olig2strong cells (Figure 3C, Figure 4A) relative
to animals on normal diet; an increase in these cells has
been previously observed in demyelinated lesions in the
adult CNS.21 This increase was not associated with a
simultaneous increase in Nkx2.2strong cells (Figure 3D,
Figure 4A). There was a strong correlation between de-
myelination score and average numbers of Olig2strong
cells in the CC (R2  0.82), and a weaker correlation with
numbers of Nkx2.2strong cells (R2 0.66) at the end of the
demyelination period (week 6). Our results suggest that
immature OPCs (Olig2strong/Nkx2.2weak) infiltrated the CC
in response to demyelination, a step required before the
initiation of remyelination. Short-term statin treatment
(weeks 4 to 6) of animals on cuprizone caused a signif-
icant decrease in Olig2strong OPCs (Figure 3C, Figure 4A)
and Nkx2.2strong cells (Figure 3D, Figure 4A), implying
that reduced progenitor numbers may have contributed
to the diminishment in initial remyelination observed with
this treatment regimen.
Simvastatin Treatment Influences Progenitors during
the Post-Cuprizone Remyelination Phase
Animals that were administered a normal diet during
weeks 7 to 9 (remyelination phase) subsequent to cupri-
Figure 3. Quantification of the impact of simvastatin on OPCs in the corpus
callosum. A, B: Coronal sections of corpus callosum of normal animals on
normal diet. OPCs (small arrowheads) were identified as having strong
staining for the transcription factors Olig2 and Nkx2.2 and showed a random
distribution pattern (brown). Weakly positive cells (large arrowheads)
were taken to be mature OLGs and were aligned in rows. Nuclei were
labeled with hematoxylin (blue). Scale bar  25 m. C: Average numbers of
Olig2strong OPCs per mm2 medial corpus callosum (CC)  SEM. Simvastatin
treatment (Simva) (weeks 4 to 6) of animals on normal diet (black bars)
caused a significant increase in Olig2strong OPCs relative to vehicle control.
Cuprizone administration (gray bars) resulted in an increase in Olig2strong
cells at this time. Simvastatin treatment during weeks 4 to 6 inhibited this
increase in Olig2strong OPCs in the CC. At week 9, vehicle treated animals on
normal diet (black bars) show an increase in Olig2strong cells compared with
week 6. At this time point, simvastatin treatment of animals on normal diet
had no significant effect on numbers of Olig2strong OPCs. Cuprizone-treated
animals showed a decrease in these cells by week 9 relative to week 6.
However, simvastatin treatment during weeks 4 to 9 or 7 to 9 caused a
significant increase in Olig2strong OPCs in the CC relative to cuprizone alone.
D: Average numbers of Nkx2.2strong OPCs per mm2 medial CC  SEM.
Simvastatin treatment (weeks 4 to 6) of animals on normal diet (black bars)
caused a significant increase in Nkx2.2strong cells in comparison with control
(vehicle  normal diet). Simvastatin treatment (weeks 4 to 6) of animals on
cuprizone (gray bars) was associated with a decrease in Nkx2.2strong OPCs in
the CC versus control (cuprizone  vehicle). By week 9, vehicle treated
animals on normal diet (black bars) showed a decrease in Nkx2.2strong cells
compared with week 6. At this time point, simvastatin treatment of animals
on normal diet caused an increase in numbers of Nkx2.2strong OPCs. Cupri-
zone administration induced a significant increase in Nkx2.2strong OPCs by
week 9. Simvastatin treatment (weeks 4 to 9) of animals on cuprizone caused
a significant decrease in numbers of Nkx2.2strong OPCs in the CC relative to
cuprizone alone. Analysis of variance P values 0.001. ns P  0.05, *P 
0.05, **P  0.01, ***P  0.001.
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zone treatment showed a trend toward a decrease in
Olig2strong cells relative to the demyelination period (Fig-
ure 3C, Figure 4B), a phenomenon previously docu-
mented by others in remyelinating lesions.21 A trend to-
ward an increase in Nkx2.2strong cell numbers at the end
of the remyelination period was also observed in these
animals (week 9; Figure 3D, Figure 4B). OPCs increase
Nkx2.2 expression and decrease Olig2 levels in associ-
ation with terminal differentiation15,22 a requirement for
remyelination to occur. Simvastatin administration during
the entire period of OPC responses (weeks 4 to 9) or
during the remyelination-only phase (weeks 7 to 9) sig-
nificantly increased Olig2strong cells. The more prolonged
simvastatin treatment regimen (weeks 4 to 9) also in-
duced a significant decrease in Nkx2.2strong cells relative
to cuprizone-vehicle controls, whereas the shorter treat-
ment regimen from weeks 7 to 9 did not (Figure 3D,
Figure 4B). This observation suggests that either simva-
statin slowed the migration of Olig2strong OPCs into the
CC such that they were only increased by week 9, that
continued myelin injury recruited more Olig2strong OPCs
to the CC, or that OPCs were maintained in an immature
state (Olig2strong/Nkx2.2weak) from simvastatin exposure.
Effects of Simvastatin Treatment on Mature
Oligodendrocytes
Mature OLG cell bodies were identified by expression of
NogoA, a marker previously demonstrated to reliably la-
Figure 4. Simvastatin impacts OPCs in the cuprizone-demyelinated corpus callosum. A: Coronal sections of corpus callosum of animals sacrificed at week 6. OPCs
were identified by strong immunostaining against Olig2 (left panels) and Nkx2.2 (right panels) (brown). Nuclei were labeled with hematoxylin (blue).
Simvastatin treatment (weeks 4 to 6) of animals on normal diet caused an increase in Olig2strong OPCs and Nkx2.2strong OPCs relative to vehicle control.
Cuprizone-treated animals demonstrated an increase in Olig2strong cells but not Nkx2.2strong OPCs at this time. These animals also demonstrated an increase in
total nuclei in the corpus callosum relative to animals on normal diet, which represented astroglial and microglial infiltration (addressed in Figure 7). Simvastatin
treatment of animals on a cuprizone diet during weeks 4 to 6 caused a relative decrease in Olig2strong and Nkx2.2strong OPCs relative to cuprizone-vehicle controls.
Scale bar  50 m. B: Coronal sections of corpus callosum of animals sacrificed at week 9. Simvastatin treatment of animals on normal diet had no effect on
numbers of Olig2strong OPCs but caused an increase in numbers of Nkx2.2strong OPCs relative to vehicle controls. Cuprizone-treated animals showed a decrease
in Olig2strong OPCs and an increase in Nkx2.2strong OPCs at week 9 relative to week 6. However, simvastatin treatment during weeks 4 to 9 or 7 to 9 caused a
significant increase in Olig2strong OPCs and decrease in Nkx2.2strong OPCs relative to cuprizone alone. Scale bar  50 m.
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bel OLGs in human and mouse adult CNS to the same
extent as other markers such as adenomatous polyposis
coli, 2,3-cyclic nucleotide 3-phosphodiesterase, and
proteolipid protein.15,25 NogoA mature OLGs were typ-
ically aligned in rows (Figure 5A).
Simvastatin Treatment Decreases Numbers of Mature
OLGs under Non-Demyelinating Conditions
Animals on normal diet demonstrated maintenance
of NogoA cell numbers over time (Figure 5B, Figure
6, A and B); there was no significant difference be-
tween OLG cell numbers from animals sacrificed at
week 6 relative to week 9 (P  0.05). The previously
mentioned increase in Olig2strong OPCs in the CC of
these animals may reflect an ongoing replacement of
mature OLGs observed in adult rodent CNS.23,24 Sim-
vastatin treatment of animals on normal diet (weeks
4–6, 4–9) caused a decrease in numbers of NogoA
cells (Figure 5B, Figure 6, A and B) relative to the
vehicle control, which is consistent with the reduced
myelin load observed with long-term treatment, and
with the conclusion that progenitor differentiation into
mature OLGs was impaired in this condition.
Simvastatin Treatment Further Decreases Numbers
of Mature OLGs during the Period of Concomitant
Demyelination and Progenitor Responses
Cuprizone caused an expected decrease in NogoA
cells at week 6, reflecting targeting of these cells by the
toxin (Figure 5B, Figure 6A). Short-term statin treatment
(weeks 4–6) of animals on cuprizone caused a further
decrease in NogoA mature OLGs relative to cuprizone-
vehicle controls (Figure 5B, Figure 6A), either reflecting
impaired progenitor differentiation into mature OLGs or a
direct cytotoxic effect on the OLGs.
Figure 5. Quantification of the effect of simvastatin on mature OLGs in the
corpus callosum. A: Mature OLG cell bodies were labeled with a NogoA-
directed antibody (brown) and nuclei were labeled with hematoxylin (blue).
Scale bar  50 m. B: Average numbers of NogoA cells per mm2 of the
medial corpus callosum (CC) ( SEM). Simvastatin treatment (weeks 4 to 6;
Simva) of animals on normal diet (black bars) caused a significant decline in
NogoA mature OLGs in the CC. Cuprizone-induced demyelination (gray
bars) was associated with a decrease in NogoA mature OLGs (week 6)
relative to animals on normal diet. Simvastatin treatment during the period of
initial OPC proliferation/maturation (weeks 4 to 6) caused a significant
reduction in NogoA cells relative to control. Although numbers of NogoA
cells were maintained over time in vehicle treated animals on normal diet
(from weeks 6 to 9), animals treated with simvastatin had a persistent
decrease in NogoA OLGs in the CC by week 9. The cuprizone-vehicle
treatment group demonstrated a recovery of NogoA OLGs at week 9
relative to week 6. However, simvastatin treatment during weeks 4 to 9 or 7
to 9 caused a significant decrease in mature OLGs in the CC. Analysis of
variance P values 0.001. ns P  0.05, *P  0.05, **P  0.01, ***P  0.001.
Figure 6. Simvastatin inhibits the recovery of mature OLGs in the demyeli-
nated corpus callosum. A: Coronal sections of corpus callosum of animals
sacrificed at week 6. Mature OLG cell bodies were labeled against NogoA
(brown) and counterstained with hematoxylin (blue). Simvastatin treatment
(weeks 4 to 6) of animals on a normal diet caused a significant decline in
NogoA mature OLGs. Cuprizone treatment was also associated with a
decrease in NogoA mature OLGs relative to animals on normal diet.
Simvastatin treatment during the period of initial OPC proliferation/matura-
tion (weeks 4 to 6) caused a further reduction in NogoA cells. B: Coronal
sections of corpus callosum of animals sacrificed at week 9. Animals on a
normal diet treated with simvastatin demonstrated a decrease in NogoA
OLGs relative to vehicle control. Simvastatin treatment during weeks 4 to 9 or
7 to 9 caused a significant decrease in mature OLGs relative to cuprizone-
vehicle controls. Scale bar  50 m.
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Simvastatin Treatment Further Decreases Numbers
of Mature OLGs during the Post-Cuprizone
Remyelination Phase
By the end of the post-cuprizone recovery phase
(weeks 7–9), the numbers of NogoA OLGs had recov-
ered to values comparable with those observed in ani-
mals on normal diet for the entire duration of the experi-
ment (P  0.05, Figure 5B, Figure 6B). In comparison,
simvastatin treated animals (weeks 4–9, 7–9) had signif-
icantly fewer NogoA cells relative to cuprizone-vehicle
controls (Figure 5B, Figure 6B), supporting the conclu-
sion that simvastatin blocked the differentiation of pro-
genitors into mature OLGs.
Effects of Simvastatin Treatment on Astrocytes
and Microglia in the Corpus Callosum
Although the cuprizone model has been demonstrated to
not have any lymphocyte infiltration or blood-brain barrier
breakdown,11 there is significant gliosis in response to
OLG injury and demyelination.26 We assessed the poten-
tial confounding impact of simvastatin on glial reactivity in
the CNS by measuring numbers of infiltrating microglia
and astrocytes in the demyelinated CC following cupri-
zone treatment. We used IBA-1 and GFAP as markers for
activated microglia and astrocytes, respectively, given
the functional demonstration that these markers are up-
regulated on glial activation.27,28
Interestingly, following statin treatment of animals on
a normal diet, there was an increase in numbers of
activated astrocytes (week 6) and microglia (week 9)
relative to vehicle control (Figure 7, B and C, respec-
tively), suggesting a glial response to statin-induced
damage to the CC.
At 6 weeks of cuprizone administration, we observed a
significant increase in numbers of activated astrocytes
(GFAP; Figure 7, A and B) and microglia (IBA-1;
Figure 7C) in the CC relative to animals on normal diet.
Simvastatin treatment of cuprizone-treated animals did
not significantly decrease gliosis relative to the respec-
tive control (Figure 7, A–C). These results indicate that
simvastatin does not dampen glial activation responses
in the brain of cuprizone-treated mice, and that any sta-
tin-induced neural response during remyelination is not
confounded by effects on glial reactivity.
Discussion
Using immunomodulatory concentrations, our study indi-
cates that long-term simvastatin therapy exerts effects on
myelin and oligodendroglial cells in normal, demyelinating,
and remyelinating environments. We demonstrate that sim-
vastatin interferes with myelin repair and maintenance by
directly impacting OPC functions and affecting mature OLG
numbers. Klopfleisch et al. (2008) have now also shown that
Figure 7. Simvastatin does not decrease gliosis
in the cuprizone model. A: Representative im-
ages of sections immunostained against GFAP
(astrocytes; brown) and counterstained with he-
matoxylin (blue). Scale bar  200 m. B: Aver-
age numbers of GFAP astrocytes per mm2 of
the corpus callosum (CC)  SEM. Simvastatin
treatment (weeks 4 to 6) of animals on normal
diet caused an increase in astrocyte numbers
relative to vehicle alone (black bars). Cuprizone
administration (gray bars) increased astrocyte
reactivity in the CC, which was not affected by
concomitant simvastatin treatment. Long-term
simvastatin treatment (weeks 4 to 9) of animals
on normal diet showed no difference in astro-
cyte reactivity relative to vehicle alone. The cu-
prizone treated animals showed a decrease in
astrocyte numbers by week 9 relative to week 6;
similar profiles were observed when simvastatin
was administered to cuprizone-fed animals. C:
Average numbers of IBA-1 microglia/macro-
phages per mm2 of the CC  SEM. Simvastatin
treatment (weeks 4 to 6) of animals on normal
diet (black bars) had no significant effect on
IBA-1 cell number in the CC. By week 6,
cuprizone administration (gray bars) caused an
increase in IBA-1 cell numbers relative to ve-
hicle controls; this was not affected when sim-
vastatin was administered. Long-term simvasta-
tin treatment (weeks 4 to 9) of animals on
normal diet was associated with an increase in
microglia reactivity relative to control. At the
end of the recovery from cuprizone-induced de-
myelination, microglia numbers were further in-
creased relative to vehicle control. Simvastatin
treatment of cuprizone-fed animals during
weeks 4 to 9 or 7 to 9 had no effect on IBA-1
cell numbers relative to cuprizone controls.
Analysis of variance P values 0.001. ns P 
0.05, *P  0.05, **P  0.01, ***P  0.001.
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treatment with statin in a range of doses also reduces my-
elin content in cuprizone-treated animals.29
Long-Term Simvastatin Treatment Interferes
with Myelin Maintenance under
Non-Demyelinating Conditions
Short-term simvastatin therapy alone did not induce any
notable effects on myelin in the CC of animals on normal
diet, consistent with previous studies showing that lova-
statin treatment (3 weeks) had no effect on myelin protein
and mRNA levels in the mouse spinal cord.8 However, we
observed that long-term simvastatin treatment of animals
on normal diet (6 weeks) resulted in a reduction in myelin
load and a loss of mature OLGs in the CC. Chronic
simvastatin treatment has been shown to significantly
reduce brain cholesterol levels in healthy mice, whereas
lovastatin does not.19
Mature oligodendrocytes are the primary producers of
cholesterol in the brain.30 Cholesterol is highly concen-
trated in oligodendroglial membranes and undergoes a
continuous turnover in myelin.31 Cholesterol is also con-
centrated in fluid microdomains in the membrane bilayer,
termed lipid rafts, which house and aggregate signaling
molecules to facilitate the initialization of intracellular sig-
naling cascades. Lipid rafts in oligodendrocytes are also
significantly distinct from those in other cell types; the
aggregation of these lipid rafts forms the myelin sheath.
Abnormal myelination has previously been observed
when cholesterol is depleted in mouse organotypic spinal
cord cultures32 or by genetic manipulation of OLGs in
vivo.30 Treatment of rat OLGs with lovastatin in vitro inhib-
its cholesterol-dependent transport of proteolipid protein
mRNA into oligodendroglial membrane processes, re-
sulting in the formation of abnormal myelin-like sheaths
devoid of this myelin protein.33 Treatment of mouse or-
ganotypic or human explant cultures with cholesterol bio-
synthesis inhibitors such as statins for prolonged periods
of time causes cell death of oligodendrocytes.32,34,35 In
addition, simvastatin may influence oligodendroglial cell
survival signaling via blockade of isoprenylation.36 In this
regard, treatment of fully myelinated mouse cerebellar
slices with both nanomolar and micromolar doses of sim-
vastatin for 6 days has been shown to induce significant
OLG cell death, which is fully rescued by supplementa-
tion with the isoprenoid farnesyl pyrophosphate.35
Increased numbers of both Olig2strong and Nkx2.2strong
OPCs in simvastatin-treated animals on normal diet likely
reflects a block in differentiation at the pre-OLG state.
These OPCs were not contributing to myelin formation
and maintenance, as evidenced by reduced myelin load
in the CC, and the loss of mature OLGs. OPC differenti-
ation is associated with the acquisition of distinct sets of
lipid rafts housing signaling molecules relevant for the
maturation process.37 Indeed, the recruitment of cy-
toskeletal-associated proteins to lipid rafts in oligoden-
drocytes is important for the initiation of myelination. Sta-
tin treatment has been associated with a decrease in
levels of membrane cholesterol and of a lipid raft marker,
flotillin, demonstrating the ability of statin-induced cho-
lesterol depletion to disrupt lipid rafts.38 The increase in
gliosis that we observed in the CC of these animals
suggests that simvastatin-induced injury to the CC could
also have promoted the recruitment of OPCs. The in-
crease in OPCs in the CC of simvastatin-treated animals
is unlikely to reflect an increase in proliferation given that
in vivo statin treatment has been previously shown not to
induce changes in mRNA levels of genes implicated in
OPC proliferation, and that statins inhibit human adult
progenitor proliferation in vitro.8,10
Simvastatin Treatment Inhibits Initial OPC
Responses to Demyelination and Impairs
Subsequent Remyelination
Simvastatin treatment inhibited both the initial OPC re-
sponses observed during cuprizone-induced demyelina-
tion, and myelin repair following return to normal diet.
These results likely reflect simvastatin’s inhibition of the
new cholesterol synthesis that is deemed important for
remyelination in the cuprizone model.26 Simvastatin treat-
ment may have interfered with myelin repair by inhibiting
lipid-raft associated signaling and cholesterol-dependent
process extension.39
The brain synthesizes its own source of cholesterol
from fetal development throughout adulthood, which can-
not be supplemented by dietary or circulating cholesterol
derived from the liver.30,40 Increases in cholesterol and
the brain-specific cholesterol metabolite 24-S-hydroxy-
cholesterol have been measured in patients with active
MS and in animals in the active phase of experimental
autoimmune encephalomyelitis.40,41 This likely either re-
flects membrane cholesterol found in debris resulting
from neuronal and oligodendroglial injury and death, or
the increase in cholesterol synthesis proposed to be
necessary for repair. The CSF of primary progressive or
patients with long-time relapse-remitting MS has reduced
levels of 24-S-hydroxycholesterol relative to healthy con-
trols41; this may reflect cell loss and consequent reduc-
tion in cholesterol production, and may suggest that re-
pair processes may be further impaired by simvastatin.
Simvastatin treatment during the period of concomitant
OPC proliferation/maturation and demyelination caused a
decrease in both Olig2strong and Nkx2.2strong OPCs. Ex-
posure to simvastatin in vitro can hinder progenitor cell
migration, inhibit proliferation, and exert a cytotoxic ef-
fect.9,10 Previous studies in the experimental autoimmune
encephalomyelitis model showed that lovastatin treat-
ment (3 weeks) enhanced OPC proliferation, differentia-
tion, and recruitment to the spinal cord.8 Such statin
therapy significantly inhibits the immune response within
the experimental autoimmune encephalomyelitis-afflicted
CNS,6 raising the issue as to whether the net observed
effects are indirectly mediated through anti-inflammatory
effects. Furthermore, when either lovastatin or simvastatin
are chronically administered daily to mice, simvastatin is
found at higher concentrations in the CNS, induces
changes in expression in a higher number of genes, and
significantly reduces brain cholesterol levels, relative to
lovastatin.19 Our data indicate that prolonged simvastatin
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treatment impeded remyelination on return to normal diet
by maintaining OPCs in an immature state (Olig2strong/
Nkx2.2weak), thereby preventing maturation into NogoA
OLGs that contribute to formation of new myelin. The
observed increase in Olig2strong OPCs in the CC at this
time is unlikely to reflect enhanced migration or prolifer-
ation given that simvastatin inhibits rodent OPC migration
and human progenitor proliferation in vitro.9,10 Our pos-
tulate is supported by the finding that OPC differentiation
requires the acquisition of distinct sets of cholesterol-
enriched lipid rafts.37 We also observed that the number
of Nkx2.2strong cells were significantly more reduced
when simvastatin was administered to cuprizone-fed an-
imals for weeks 4 to 9 in comparison with weeks 7 to 9,
thereby indicating that prolonged exposure to the drug
may be associated with more pronounced effects on
these cells. Nkx2.2 expression is increased before termi-
nal oligodendrocyte differentiation.15,22 The loss of ma-
ture OLGs when simvastatin was administered during the
demyelination or remyelination phases is supported by
cytotoxic effects of statins on mature OLGs in vitro,9,34,35
but may also reflect the lack of maturation of progenitors
under these treatment regimens.
Conclusion
Together, our data support the conclusion that simvasta-
tin blocks the differentiation of progenitors into mature
myelinating cells, thereby inhibiting remyelination in the
cuprizone model. We also show the importance of cho-
lesterol and isoprenoid synthesis pathways in processes
of myelin maintenance and remyelination. Our findings
also highlight the necessity of monitoring long-term ef-
fects of systemically applied therapies that can access
the CNS, particularly those that can impact cell types that
are postulated to be targeted in neurological disease
processes and that are implicated in any tissue repair
process. The expression of the enzyme inhibited by st-
atins, HMG Co-A reductase, in all cell types along with
the penetration of the lipophilic simvastatin into the brain
parenchyma, together suggest potential direct effects of
statins on neural cell properties.
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